GSK Plc - ADR

GSK Plc - ADR

GSK

Market Cap$74.43B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
GSK Plc - ADRGSK Plc - ADR17.94.43%22%2.5-

Earnings Call Q1 2025

April 30, 2025 - AI Summary

Strong Q1 Performance: GSK reported a 4% increase in group sales to £7.5 billion, with core operating profit up 5% and core earnings per share at 44.9 pence. The growth was primarily driven by specialty medicines, which saw a remarkable 17% increase, contributing to overall momentum despite a 6% decline in vaccine sales.
Upcoming Product Approvals and Launches: Key product approvals are anticipated in 2025, including Nucala for COPD on May 7 and Blenrep on July 23. Nucala is expected to penetrate the COPD market effectively due to its broader patient applicability and recent clinical data emphasizing hospitalization reduction, while Blenrep aims to capture the second-line treatment market in multiple myeloma despite concerns regarding ocular toxicity management.
Financial Guidance and Growth Projection: GSK is reaffirming its 2025 financial guidance, projecting sales growth of 3% to 5% and operating profit growth of 6% to 8%. The company expects low double-digit percent growth in specialty medicines and anticipates higher royalty income, now estimated between £750 million to £800 million, bolstering investor confidence.

Exclusive for Stockcircle Pro members

Sign upSign Up
$35.25

Target Price by Analysts

6.3% downsideGSK Plc Target Price DetailsTarget Price
$38.33

Current Fair Value

1.8% upside

Undervalued by 1.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$74.43 Billion
Enterprise Value$70.59 Billion
Dividend Yield$1.55156 (4.42831215970962%)
Earnings per Share$1.26
Beta0.27
Outstanding Shares2,040,000,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio17.86
PEG32.32
Price to Sales2.51
Price to Book Ratio6.27
Enterprise Value to Revenue2.24
Enterprise Value to EBIT13.62
Enterprise Value to Net Income22
Total Debt to Enterprise0.01
Debt to Equity0.04

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Glaxosmithkline plc

CEO: Emma Walmsley